Filtered By:
Condition: Autoimmune Disease
Drug: Rituxan
This page shows you your search results in order of date.
Order by Relevance | Date
Total 47 results found since Jan 2013.
Narrative Review of Anti-CD3 Antibody and Anti-CD20 Antibody: Immunotherapeutic Strategies to Treat and Prevent Type 1 Diabetes
CONCLUSION: Immunotherapeutic can be a better option for preventing and protecting type one diabetes. Since, the existing literature does not have enough data to support any single drug concluding the same will not be appropriate. Hence further studies are required wherein different drugs can be compared with similar sample sizes for each group of drugs.PMID:36415095 | DOI:10.2174/2772270817666221122103029
Source: Adv Data - November 23, 2022 Category: Epidemiology Authors: Prajakta Kashalikar Shivani Desai Avinash Sanap Madhura Shekatkar Ramesh Bhonde Source Type: research
Complete resolution of acquired angioedema from splenic marginal zone lymphoma after treatment with rituximab
Acquired angioedema (AAE) due to C1 esterase inhibitor (C1-INH) deficiency is clinically similar to hereditary angioedema (HAE), but typically develops in older patients. There is invariably an underlying disease such as a lymphoproliferative disorder, autoimmune condition, solid tumor, etc. that either drives autoantibody production against normal C1-INH and/or causes consumptive depletion of normally functioning C1-INH.
Source: Annals of Allergy, Asthma and Immunology - November 1, 2022 Category: Allergy & Immunology Authors: B. Wang Tags: M124 Source Type: research
Deconvoluting the heterogeneity of SLE: The contribution of ancestry
Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disorder with a prominent genetic component. Evidence has shown that individuals of non –European ancestry experience the disease more severely, exhibiting an increased incidence of cardiovascular disease, renal involvement, and tissue damage compared with European ancestry populations. Furthermore, there seems to be variability in the response of individuals within different ancestr al groups to standard medications, including cyclophosphamide, mycophenolate, rituximab, and belimumab.
Source: Journal of Allergy and Clinical Immunology - November 29, 2021 Category: Allergy & Immunology Authors: Katherine A. Owen, Amrie C. Grammer, Peter E. Lipsky Source Type: research
M180 persistent hypogammaglobulinemia in a pediatric patient following rituximab treatment for autoimmune encephalitis
We describe an adolescent patient with autoimmune encephalitis who experienced prolonged B-cell depletion and persistent hypogammaglobulinemia following Ritixumab, with eventual B-cell recovery but persistent hypogammaglobulinemia and absence of isotype-switched memory B cells(CD19+CD27+IGD-IgM-).
Source: Annals of Allergy, Asthma and Immunology - November 1, 2021 Category: Allergy & Immunology Authors: K. Lanier, P. Mustillo Source Type: research
Comparison of Guidelines for Management of Pemphigus: a Review of Systemic Corticosteroids, Rituximab, and Other Immunosuppressive Therapies
AbstractPemphigus is a severe autoimmune bullous dermatosis that affects the skin and/or mucosa, and it may be life-threatening without proper treatment. The guidelines and/or consensus statements for treatment vary widely between groups. We selected 6 guidelines and consensus statements established by different associations about the management of pemphigus vulgaris (PV) and/or pemphigus foliaceus (PF) to review, compare, and contrast the similarities and differences of these recommendations and provide optimal management suggestions to physicians. Corticosteroids remain a first-line therapy for pemphigus, but there are m...
Source: Clinical Reviews in Allergy and Immunology - August 4, 2021 Category: Allergy & Immunology Source Type: research
Evaluation of Hypersensitivity Reactions in Pediatric Patients Using Biological Drugs
Conclusion: It was reported that 6.64% of the patients who received biologic drug therapy for various reasons in our hospital had hypersensitivity. The most common culprit agent was rituximab, and most of the reactions were immediate reactions.Int Arch Allergy Immunol
Source: International Archives of Allergy and Immunology - June 3, 2021 Category: Allergy & Immunology Source Type: research
FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
● Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic...
Source: Roche Media News - April 13, 2021 Category: Pharmaceuticals Source Type: news
COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology
J Korean Med Sci. 2021 Mar 29;36(12):e95. doi: 10.3346/jkms.2021.36.e95.ABSTRACTThe coronavirus disease 2019 (COVID-19) pandemic has caused more than 100 million infections and 2 million deaths worldwide. In up to 20% of cases, COVID-19 infection can take a severe, life-threatening course. Therefore, preventive measures such as mask-wearing, hand hygiene, and social distancing are important. COVID-19 vaccines that use novel vaccine technology can prevent up to 95% of infections. However, the uncertainty regarding the efficacy and safety of vaccination in patients with autoimmune inflammatory rheumatic disease (AIIRD), who ...
Source: J Korean Med Sci - March 30, 2021 Category: General Medicine Authors: Jin Kyun Park Eun Bong Lee Kichul Shin Yoon Kyoung Sung Tae Hwan Kim Seong Ryul Kwon Myeung Su Lee Seung Jae Hong Byoong Yong Choi Shin Seok Lee Han Joo Back Korean College of Rheumatology Task Force for COVID-19 Vaccine Guidance for Patients with Autoimm Source Type: research
